TMEM9

TMEM9 is a glycosylated transmembrane protein of the endolysosomal system that regulates vesicular ion homeostasis, acidification, and signaling. It serves as an accessory β-subunit of endosomal ClC-3/4/5 Cl⁻/H⁺ antiporters, where cryo-EM structures show it inhibits ClC-3 by sealing the cytosolic Cl⁻ pathway in a PtdIns(3,5)P₂-dependent manner (PMID:40670814). TMEM9 also facilitates v-ATPase assembly, promoting vesicular acidification and lysosomal degradation of APC, which hyperactivates Wnt/β-catenin signaling in colorectal cancer and hepatocellular carcinoma, with β-catenin transcriptionally activating TMEM9 to form a positive feedback loop (PMID:30374053, PMID:32380568). Additionally, TMEM9 activates Rab9-dependent alternative autophagy by binding Beclin1 through its Bcl-2-binding domain in a glycosylation-dependent manner, displacing Bcl-2 and inducing LC3-independent autophagosome formation (PMID:39078420).

1. 2002 Medium

   Establishing TMEM9 as a glycosylated endolysosomal transmembrane protein resolved its subcellular context and post-translational processing, setting the stage for understanding its organelle-specific functions.

   Evidence GFP-tagged TMEM9 expressed in COS-1 cells co-localized with LAMP1 by fluorescence microscopy; Western blot revealed multiple N-glycosylated forms

   PMID:12359240

   Open questions at the time

   • No functional role assigned; localization based on overexpressed GFP fusion only
   • Endogenous protein localization not confirmed
   • Topology within endolysosomal membranes not determined
2. 2018 High

   Discovery that TMEM9 facilitates v-ATPase assembly and promotes lysosomal APC degradation revealed TMEM9 as a critical amplifier of Wnt/β-catenin signaling, linking endosomal acidification to oncogenic pathway activation.

   Evidence Proteomics, co-IP of TMEM9–v-ATPase, v-ATPase assembly and acidification assays, APC degradation assays, TMEM9 KO in vitro/in vivo in colorectal cancer models

   PMID:30374053

   Open questions at the time

   • Direct binding interface between TMEM9 and v-ATPase subunits not structurally resolved
   • Whether TMEM9 regulates v-ATPase independently of its CLC antiporter role is unclear
   • APC degradation selectivity mechanism not defined
3. 2020 High

   Extending the v-ATPase/APC axis to liver physiology and hepatocellular carcinoma established TMEM9 as a tissue-general regulator of Wnt signaling, demonstrating its requirement for hepatic regeneration.

   Evidence Tmem9 knockout mice showed impaired liver regeneration with elevated APC and reduced Wnt signaling; v-ATPase/lysosomal inhibitor phenocopied the defect; validated in HCC cell lines

   PMID:32380568

   Open questions at the time

   • Whether TMEM9's regeneration role extends to other rapidly renewing tissues is unknown
   • Contribution of autophagy versus lysosomal degradation to APC turnover not distinguished
4. 2024 High

   Identification of TMEM9 as an activator of Rab9-dependent alternative autophagy via glycosylation-dependent Beclin1 binding uncovered a second major cellular function independent of classical autophagy.

   Evidence Reciprocal co-IP of TMEM9–Beclin1, domain mapping to Bcl-2-binding region, glycosylation mutants abolishing the interaction and lysosomal localization, Rab9/LC3 co-localization, autophagy flux assays

   PMID:39078420

   Open questions at the time

   • Physiological stimuli triggering TMEM9-dependent alternative autophagy are not identified
   • Whether TMEM9's autophagy and v-ATPase functions are coordinated or mutually exclusive is unclear
   • In vivo validation of the alternative autophagy pathway via TMEM9 is lacking
5. 2024 Medium

   Demonstration that TMEM9 activates MEK/ERK/STAT3 signaling to drive VEGF-mediated angiogenesis in lung adenocarcinoma expanded its oncogenic repertoire beyond Wnt/β-catenin.

   Evidence TMEM9 KD/OE in LUAD cells, VEGF-neutralizing antibody rescue, pathway Western blots, HUVEC co-culture angiogenesis assays, in vivo tumor models

   PMID:38664392

   Open questions at the time

   • Whether MEK/ERK/STAT3 activation is downstream of v-ATPase assembly or a distinct mechanism is not resolved
   • Direct molecular link between TMEM9 and MEK/ERK pathway initiation not established
6. 2025 High

   Cryo-EM structures of TMEM9 bound to ClC-3 established it as a bona fide accessory β-subunit of endosomal CLC antiporters, resolving its inhibitory mechanism through occlusion of the cytosolic Cl⁻ pathway and identifying PtdIns(3,5)P₂ as a stabilizing lipid cofactor.

   Evidence Cryo-EM structure determination of TMEM9–ClC-3 complex; biochemical demonstration of PtdIns(3,5)P₂ requirement; interaction validated with ClC-4 and ClC-5

   PMID:40670814

   Open questions at the time

   • Whether TMEM9 regulation of CLC antiporters is dynamic in response to cellular signals is unknown
   • Functional consequences of TMEM9-mediated CLC inhibition for cargo sorting and endosomal maturation are not fully characterized
   • Structural basis for TMEM9 versus TMEM9B specificity among CLC family members not determined
7. 2025 Medium

   TMEM9 regulation of complement activation via ATP6V0D1 in microglia connected its v-ATPase function to neuroinflammation and synapse elimination in Alzheimer's disease models.

   Evidence TMEM9 KD/OE in BV2 cells and 5xFAD mice; C1q activation and synaptic engulfment assays

   PMID:39871402

   Open questions at the time

   • Whether TMEM9's microglial role involves CLC antiporter regulation in addition to v-ATPase is untested
   • Mechanism linking v-ATPase to C1q activation not molecularly defined
   • Single disease model without independent replication

• How TMEM9's dual roles as a CLC antiporter subunit and v-ATPase assembly factor are coordinated, whether these functions are mutually exclusive or operate on distinct subcellular pools, and the physiological triggers that switch between its acidification, signaling, and autophagy functions remain unresolved.
• No integrated model reconciling CLC regulation and v-ATPase facilitation
• Structural basis of TMEM9–v-ATPase interaction unknown
• In vivo role of TMEM9-dependent alternative autophagy not tested